Current Report Filing (8-k)
19 October 2022 - 11:08PM
Edgar (US Regulatory)
0001711754
false
0001711754
2022-10-19
2022-10-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 19, 2022
|
INMUNE BIO INC. |
|
|
(Exact name of registrant as specified in charter) |
|
Nevada |
|
001-38793 |
|
47-5205835 |
(State or other jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
of incorporation) |
|
|
|
Identification No.) |
225
NE Mizner Blvd., Suite 640,
Boca Raton, Florida 33432
(Address of Principal Executive Offices) (Zip Code)
(858) 964 3720
(Registrant’s Telephone Number, Including
Area Code)
Not Applicable
(Former Name or Former Address, If Changed Since
Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.001 per shares |
|
INMB |
|
The NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other
Events.
On
October 19, 2022, INmune Bio Inc. issued a press release announcing positive solid tumor data in multiple cancer lines resistant to
NK killing that can be overcome with administration of INKmune. A copy of the press release is attached herewith as
Exhibit 99.1.
The Company is filing as Exhibit 99.2 to this Current
Report on Form 8-K a slide deck that the Company intends to use in a presentation.
The information contained in the Investor Presentation
is summary information that is intended to be considered in the context of the Company’s Securities and Exchange Commission (“SEC”)
filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company
undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time
to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents
with the SEC, through press releases or through other public disclosure.
Item 9.01 Financial statements and Exhibits
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
INMUNE BIO INC. |
|
|
Date: October 19, 2022 |
By: |
/s/ David Moss |
|
|
David Moss |
|
|
Chief Financial Officer |
2
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Apr 2024 to May 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From May 2023 to May 2024